View Author
polymorphism study patient association pharmacogenetic clopidogrel response effect treatment heart platelet erasmus universiteit rotterdam warfarin restenosi allele receptor statin aspirin result therapy disease mmp 2 cyp 2c genotype mmp 3 resistance clin pharmacol variation netherland aspirin resistance haplotype heart failure matrix signi pharmacol fluence table population variant 3 gene polymorphisms event b-blocker rotterdam trial metalloproteinase meta-analysi ef ficacy ficant blood outcome antiplatelet signi ficant association failure clopidogrel resistance artery disease analysis vkorc signi ficantly erasmu review prasugrel level infarction pharmacogenomic factor ace-inhibitor thromb march universiteit protein evidence promoter enzyme downloaded gender bene fit metoprolol variability ficacy braunwald e
3 Most Recent Publications
|
A systematic review on pharmacogenetics in cardiovascular disease: Is it ready for clinical application?
(Article)
Verschuren, J.J.W. Trompet, S. Wessels, J.A.M. Guchelaar, H.J. Maat, M.P.M. de Simoons, M.L. Jukema, J.W. |
2012-01-01
|
|
Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality
(Article)
Verschuren, J.J.W. Doevendans, P.A. Zwinderman, A.H. Trompet, S. Craen, Anton J.M. de Westendorp, R.G.J. Ikram, M.A. Tio, R.A. Kanse, Sandip M Winter, R.J. de Jukema, J.W. Slagboom, P.E. Pons, D. |
2011-01-01
|
|
Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention: Is there still room for determining genetic variation of MMPs for assessment of an increased risk of restenosis?
(Article)
Verschuren, J.J.W. Sampietro, M.L. Maat, M.P.M. de Doevendans, P.A. Jukema, J.W. Pons, D. Trompet, S. Ewing, M.M. Quax, P.H.A. Knijff, P. de Zwinderman, A.H. Winter, R.J. de Tio, R.A. |
2010-12-01
|